EA201690217A1 - Способ и диагностический набор для контроля рассеянного склероза (pc) - Google Patents

Способ и диагностический набор для контроля рассеянного склероза (pc)

Info

Publication number
EA201690217A1
EA201690217A1 EA201690217A EA201690217A EA201690217A1 EA 201690217 A1 EA201690217 A1 EA 201690217A1 EA 201690217 A EA201690217 A EA 201690217A EA 201690217 A EA201690217 A EA 201690217A EA 201690217 A1 EA201690217 A1 EA 201690217A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diagnostic kit
patient suffering
control
multiple sclerosis
kinurenin
Prior art date
Application number
EA201690217A
Other languages
English (en)
Inventor
Жиль Гиймен
Чай Кят Лим
Брюс Джеймс Бру
Original Assignee
Дайэнти Мс Лимитэд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайэнти Мс Лимитэд filed Critical Дайэнти Мс Лимитэд
Publication of EA201690217A1 publication Critical patent/EA201690217A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Способ и диагностический набор для оценки тяжести PC у пациента, страдающего PC, или для контроля прогрессирования PC у пациента, страдающего PC, или для контроля эффекта терапии, назначенной пациенту, страдающему PC. В способе и диагностическом наборе уровень одного или нескольких соединений метаболического пути кинуренина в ткани или жидкости организма пациента, страдающего PC, сравнивают с контрольным значением для одного или нескольких соединений метаболического пути кинуренина.
EA201690217A 2013-07-18 2013-07-18 Способ и диагностический набор для контроля рассеянного склероза (pc) EA201690217A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055902 WO2015008111A1 (en) 2013-07-18 2013-07-18 Method and prognostic kit for monitoring multiple sclerosis (ms)

Publications (1)

Publication Number Publication Date
EA201690217A1 true EA201690217A1 (ru) 2016-07-29

Family

ID=52345780

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690217A EA201690217A1 (ru) 2013-07-18 2013-07-18 Способ и диагностический набор для контроля рассеянного склероза (pc)

Country Status (9)

Country Link
US (1) US20160161507A1 (ru)
EP (1) EP3022558A4 (ru)
JP (1) JP6290398B2 (ru)
CN (1) CN105556306B (ru)
AU (1) AU2013394569A1 (ru)
CA (1) CA2918447A1 (ru)
EA (1) EA201690217A1 (ru)
IL (1) IL243670A0 (ru)
WO (1) WO2015008111A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3373007A1 (en) * 2017-03-06 2018-09-12 Metabolomic Discoveries GmbH Biomarkers for diagnosis and progression of primary progressive multiple sclerosis (ppms)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL124444A0 (en) * 1998-05-12 1998-12-06 Svetlana Dolina Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
EP1904853A1 (en) * 2005-07-11 2008-04-02 AstraZeneca AB Method for diagnosing multiple sclerosis
HUP0700051A2 (en) * 2007-01-17 2008-09-29 Univ Szegedi Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation
AT9843U1 (de) * 2007-03-27 2008-04-15 Kepplinger Berthold Dr Messung von biologischen markern
AU2010326737A1 (en) * 2009-12-01 2012-06-07 Metanomics Health Gmbh Means and methods for diagnosing multiple sclerosis
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway

Also Published As

Publication number Publication date
WO2015008111A1 (en) 2015-01-22
US20160161507A1 (en) 2016-06-09
AU2013394569A1 (en) 2016-02-18
CN105556306B (zh) 2018-04-20
CA2918447A1 (en) 2015-01-22
EP3022558A4 (en) 2017-02-15
IL243670A0 (en) 2016-03-31
EP3022558A1 (en) 2016-05-25
JP6290398B2 (ja) 2018-03-07
CN105556306A (zh) 2016-05-04
JP2016525215A (ja) 2016-08-22

Similar Documents

Publication Publication Date Title
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
PH12016502167A1 (en) Hdl theraphy markers
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
IL255440B (en) Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
GB2519907A (en) Systems and methods for diagnosing strokes
EA201790444A1 (ru) Hsp90-направленная визуализация и терапия воспаления и инфекции
MX2015015907A (es) Metodo no invasivo objetivo para cuantificar el grado de comezon mediante el uso de mediciones psicofisiologicas.
HK1214752A1 (zh) 由產甲烷菌引起或與之相關的疾病及病狀的診斷、選擇及治療方法
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
HK1223129A1 (zh) 基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用
MX2017010516A (es) Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea.
TN2015000315A1 (en) Methods of treating cardiovascular indications
NZ712300A (en) Falz for use as a target for therapies to treat cancer
EA201690217A1 (ru) Способ и диагностический набор для контроля рассеянного склероза (pc)
MA41782A (fr) Traitement de patients atteints de diabète de type 2
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира